Engineering#13 in June 2026 EditionMicrofluidic organ-on-a-chip platform for continuous pharmacokinetic monitoring of targeted oncology drugs
Alisa Bennett, Hiroki Mori, Carlos Da Silva et al.
OPENSTEM EDITORIAL SUMMARY
What the research examines
Biomedical engineers interconnect liver, vascular, and tumor microfluidic compartments on a single elastomer platform with integrated electrochemical aptamer sensors, tracking dynamic therapeutic metabolite concentrations and tumor apoptosis in real time.
Why it may matter
Drastically reduces animal testing requirements while providing human-relevant predictive preclinical pharmacology data.
What to examine carefully
Hydrophobic drug absorption into polydimethylsiloxane (PDMS) channels can skew quantitative pharmacokinetic calculations.
Editorial scope: This is a concise, independently written introduction based on the publisher information, not a full systematic review or independent replication. It must not replace reading the original methods, limitations and conclusions.
STUDENT RESEARCH LENS · ORIGINAL OPENSTEM NOTES
Try a small, reproducible follow-up
Model multi-compartment drug clearance and metabolic conversion kinetics using coupled ordinary differential equations in Python.
Questions to investigate
- How were microfluidic surface chemical modifications verified to eliminate non-specific drug molecule absorption?
- What correlation was demonstrated between chip drug-clearance curves and human clinical trial pharmacokinetic profiles?
These are independently proposed educational investigations, not activities that the original research authors claim to have completed.
Publication & researcher information
JournalLab on a Chip
Published online2026-06-17
Authors (selected)Alisa Bennett, Hiroki Mori, Carlos Da Silva et al.
University / laboratoryWyss Institute, Harvard University
CountryUnited States
Multi-author research may involve universities in several countries. Unverified institutions and contact addresses are not inferred from authors' names.